Join us as we explore the future of CNS drug development.
CNS drug development is entering a new era, driven by advances in artificial intelligence, biomarker science, digital health technologies, and precision medicine. This insightful workshop will examine how these innovations are transforming the development of therapies for neurodegenerative and neurological disorders by accelerating target identification, optimizing clinical trial design, improving patient selection, and enhancing the prediction of treatment response.
Through expert presentations, attendees will gain valuable insights into the evolving role of biological, digital, imaging, and wearable biomarkers in advancing more efficient, data-driven drug development strategies. The workshop will showcase real-world applications, emerging technologies, and new opportunities to bring more targeted, personalized, and potentially disease-modifying therapies to patients.
Designed for clinicians, researchers, and industry professionals, this session offers a practical perspective on the innovations shaping the future of CNS research and the next generation of therapeutic development.
Agenda
08:30 – 08:50 | Welcome & Breakfast
08:50 – 09:00 | Introduction
09:00 – 09:30 | Gary Zammit, PhD | Founder and Executive Chairperson | Clinilabs
09:30 – 10:00 | Professor John Harrison, PhD | Associate Professor | Alzheimer Center Amsterdam
10:00 – 10:30 | Lynne Hughes, BMed Sci, PhD, PMP | Chief of Staff | GAP Foundation
10:30 – 10:45 | Coffee Break
10:45 – 11:15 | Chris Lynch, Acting CEO & Director of Policy, Research, Communication & Publications | Alzheimer’s Disease International
11:15 – 11:55 | Andreas Borta, PhD | Chief Medical Officer | Teitur Trophics
11:55 – 12:25 | Tim Williams, PhD | Chief Medical Officer | Amandala Neuro
12:25 – 12:35 | Closing Remarks
12:35 – 13:35 | Networking Lunch
